Transformational Therapeutics
• Our next-generation therapeutics are designed to transform patient outcomes in diseases of high unmet medical needs.
• Our drugs combine the best features of biologic and small molecule drug classes into easy to produce and deliver, small synthetic peptides with high target specificity, and are based on critical sequences within a native homeostatic protein.
• The peptides work by regulating key elements driving fibrosis and solid tumor cancers, including the dampening of mechanotransduction between the fibroblasts and their surrounding extracellular matrix (ECM) and ability to specifically target the formation of collagen lineage specific pathological myofibroblasts..
Focus Areas
• Our focus is on fibro-inflammatory disease and cancer within areas of the high medical need including orphan diseases.
• Our lead focus area is scleroderma, a disease with no cure overall, and no approved therapy for skin fibrosis that can lead to crippling of the hands.
• Other focus areas include Interstitial lung disease (ILD) and solid tumor cancers which are diseases of high morbidity and mortality. We are also developing diagnostics that will provide unique opportunities in personalized medicine in these target diseases.
International Partners
• We create long-term partnerships with top international institutes and experts to maximize the creativity, breath, speed and quality of our drug discovery and development process.
Cell-Cell, Cell-Matrix Interaction
• BLR Bio combines a strong history and current activity in basic and molecular biology, biochemistry, pathology, applied drug discovery/ development, and clinical fields.
• We focus on cell/cell and cell/matrix interactions and the role of surrounding micro- and macro-environments in response to injury/stress and its translation to normal wound healing versus impaired cell and organ function (disease).